Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Rating) in a report issued on Saturday morning. The brokerage issued a buy rating on the stock.

Shares of Trinity Biotech stock opened at $1.29 on Friday. Trinity Biotech has a one year low of $0.86 and a one year high of $3.66. The stock’s 50-day moving average is $1.13 and its 200 day moving average is $1.32. The firm has a market cap of $34.72 million, a price-to-earnings ratio of 14.33 and a beta of 1.33.

Trinity Biotech (NASDAQ:TRIBGet Rating) last announced its earnings results on Monday, April 11th. The company reported $0.06 EPS for the quarter. Trinity Biotech had a negative return on equity of 27,745.46% and a net margin of 0.94%. The company had revenue of $19.53 million for the quarter.

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Trinity Biotech in the first quarter worth approximately $40,000. Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the first quarter worth approximately $27,000. Whitefort Capital Management LP boosted its holdings in Trinity Biotech by 1,067.8% in the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock worth $434,000 after acquiring an additional 374,449 shares in the last quarter. Highbridge Capital Management LLC bought a new position in Trinity Biotech in the first quarter worth approximately $1,221,000. Finally, Hunter Associates Investment Management LLC boosted its holdings in Trinity Biotech by 5.5% in the first quarter. Hunter Associates Investment Management LLC now owns 2,412,116 shares of the company’s stock worth $2,557,000 after acquiring an additional 125,966 shares in the last quarter. Institutional investors own 25.79% of the company’s stock.

Trinity Biotech Company Profile (Get Rating)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

See Also

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.